Æterna Zentaris Revenu Q/Q
Quel est le Revenu Q/Q de Æterna Zentaris?
Le Revenu Q/Q de Æterna Zentaris, Inc. est -99.81%
Quelle est la définition de Revenu Q/Q?
La croissance trimestrielle du chiffre d'affaires, d'une année sur l'autre , correspond à l'augmentation du chiffre d'affaires d'une entreprise par rapport à la performance du trimestre correspondant d'un exercice précédent, exprimée en pourcentage.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Revenu Q/Q des entreprises dans Health Care secteur sur TSX par rapport à Æterna Zentaris
Que fait Æterna Zentaris?
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Entreprises avec revenu q/q similaire à Æterna Zentaris
- Micron Solutions a Revenu Q/Q de -99.87%
- Metso Oyj a Revenu Q/Q de -99.87%
- MedinCell S.A a Revenu Q/Q de -99.87%
- Assure a Revenu Q/Q de -99.85%
- Pritish Nandy Communications Ltd a Revenu Q/Q de -99.85%
- JPMorgan Russian Securities Plc a Revenu Q/Q de -99.83%
- Æterna Zentaris a Revenu Q/Q de -99.81%
- American Resources a Revenu Q/Q de -99.79%
- Sintex Plastics Technology a Revenu Q/Q de -99.79%
- Monarch Gold a Revenu Q/Q de -99.73%
- AHAlife a Revenu Q/Q de -99.72%
- Mulvihill S Split a Revenu Q/Q de -99.72%
- Prabhat Telecoms (India) a Revenu Q/Q de -99.67%